Lights and shadows of the treatment with proton pump inhibitors in patients after myocardial infarction

Proton pump inhibitors (PPIs) are currently one of the most effective and most widely used drugs in the prevention and treatment of disorders associated with excessive secretion of hydrochloric acid. Recent reports suggest that polytherapy with PPI, clopidogrel and acetylsalicylic acid in patients after percutaneous coronary intervention is associated with the possibility of adverse interactions in the form of, inter alia, acute coronary syndromes, stroke, and even death. The latest research clearly indicate that simultaneous use of proton pump inhibitors together with dual antiplatelet therapy does not increase the risk of adverse cardiovascular events.

Read full text »

LOX inhibitors – New therapeutic aim to fight breast cancer metastases into bones

iStock_000019976173_DoubleDiscovery of scientists from University of Sheffield’s Department of Human Metabolism and University of Copenhagen opens a new therapeutic window in case of patients with invasive form of breast cancer. They showed that Lysyl oxidase homolog 2 (LOXL 2) significantly contributes to development of breast cancer metastases into bones and probably into lungs. Read full text »

Cholinesterase inhibitors – lower risk of heart attack and death in Alzheimer’s disease patients

The group of drugs used in Alzheimer’s disease therapy are cholinesterase inhibitor(ChEI). It turns out that their influence on cranial nerve X and anti-inflammatory action may be useful in prophylaxis of cardiovascular diseases. Authors of a research published in European Heart Journal have shown that ChEI intake may significantly decrease the risk heart attack and death. Read full text »